Neoantigen - OmicsDI

Show results for

Unknown (1325)
Genomics (338)
Transcriptomics (113)
Proteomics (68)
Clinical (22)
Other (18)
Genomic (8)
Methylation profiling (2)
Models (1)

Organisms

Homo sapiens (115)
Mus musculus (68)
Streptomyces coelicolor (48)
Pseudomonas aeruginosa PA103 (48)
Bartonella quintana JK 31 (48)
Bombyx mori (48)
Onchocerca volvulus (48)
Klebsiella pneumoniae (48)
Musca domestica (48)
Brugia malayi (48)
Schizosaccharomyces pombe (48)
Oryza sativa (48)
Cnidaria (48)
Streptomyces coelicolor A3(2) (48)
Sus scrofa (48)
Human immunodeficiency virus 1 (48)
Oryza sativa Indica Group (48)
Eukaryota (48)
Sinorhizobium meliloti BL225C (48)
Vitis (48)
Sus scrofa domesticus (48)
Ostreococcus tauri (48)
Saccharomyces cerevisiae (48)
Synechocystis sp. PCC 6803 (48)
Populus tremula x Populus alba (48)
Olavius algarvensis Gamma 1 endosymbiont (48)
Vitis vinifera (48)
Rattus norvegicus (1)
Escherichia coli (1)
Rattus rattus (1)

Organisms

Homo sapiens (129)
Mus musculus (67)
unidentified (1)

Repository

ENA (296)
geo (132)
pride (48)
EGA (38)
MassIVE (12)
dbGaP (8)
biostudies-arrayexpress (5)
iProX (4)
jPOST (4)
BioModels (1)

Tissue

Cell culture (14)
Lung (7)
Epithelial cell (7)
B cell (5)
Blood (5)
Permanent cell line cell (3)
Skin (2)
Leukocyte (2)
Brain (2)
Colon (2)
Epithelial cell of skin gland (1)
Mesothelial cell of pleura (1)
SW-620 cell (1)
MiaPaCa-2 cell (1)
Colorectal adenocarcinoma cell line (1)
Endocrine pancreas (1)
Cervical carcinoma cell (1)
Melanoma cell (1)
Pancreatic cancer cell line (1)
Lymphoblast (1)
Epithelial cell of lung (1)
Cerebellum (1)
Melanocyte (1)
Peripheral blood (1)
Islet of Langerhans (1)
Lymph node (1)
Bone marrow (1)
Blood serum (1)
Myeloid cell (1)
Cell suspension culture (1)

Disease

Colorectal Neoplasms (7)
Colon cancer (5)
Lung cancer (4)
Neoplasms (3)
Non-small cell lung carcinoma (3)
Adenocarcinoma (2)
Carcinoma (2)
Colorectal Cancer (2)
Lung adenocarcinoma (2)
Melanoma (2)
Colorectal cancer (2)
Acute leukemia (2)
Carcinoma of colon and rectum (1)
Advanced (1)
Melanoma (1)
Neoplasm Metastasis (1)
Colorectal cancer (1)
Lung Neoplasms (1)
Melanomatosis (1)
Fibrolamellar carcinoma (1)
Lung non-squamous non-small cell carcinoma (1)
Skin melanoma (1)
Diffuse gastric cancer (1)
Type 1 diabetes mellitus (1)
Hepatocellular carcinoma (1)
Brain glioblastoma multiforme (1)
Lymphoma (1)
Pancreatic ductal adenocarcinoma (1)
Malignant pleural mesothelioma (1)
Neuroblastoma (1)

Technology Type

Mass Spectrometry (48)
Shotgun proteomics (17)
Affinity purification coupled with mass spectrometry proteomics (14)
Immunopeptidomics (8)
Bottom-up proteomics (5)
Data-dependent acquisition (4)
Data-independent acquisition (3)
Top-down proteomics (3)
SRM/MRM (2)
ILLUMINA, Illumina HiSeq 2500 (1)
Proteogenomics (1)
Gel-based experiment (1)

Instrument Platform

Orbitrap Fusion Lumos (4)
Illumina NovaSeq 6000 (2)
Orbitrap Exploris 480 (2)
Illumina HiSeq X (1)
Illumina HiSeq 2500 (1)
ThermoFisher Orbitrap (1)
LTQ Orbitrap Elite (1)
TripleTOF 5600 (1)
Orbitrap Eclipse (1)
Orbitrap Fusion (1)
TimsTOF SCP (1)
Q Exactive (1)

Publication Date

2025 (41)
2024 (39)
2026 (30)
2023 (29)
2021 (22)
2022 (17)
2020 (6)
2019 (5)
2018 (5)
2017 (5)
2008 (1)
2015 (1)

IsPrivate

False (1)

Submitter Keywords

Machine Learning Model (1)

First Public Date

2025 (51)
2024 (47)
2026 (46)
2022 (40)
2023 (36)
2021 (27)
2019 (16)
2020 (11)
2018 (9)
2017 (9)
2015 (4)

Modelling Approach

Other (1)

Study status

Recruiting (6)
Completed (6)
Active, not recruiting (4)
Not yet recruiting (2)
Suspended (1)
Terminated (1)
Withdrawn (1)
Not provided (1)

Study type

Interventional (19)
Observational (3)
RNA-seq of coding RNA from single cells (2)
DNA-seq (1)
Transcription profiling by array (1)
RNA-seq of coding RNA (1)

Release Date

2022 (209)
2021 (204)
2023 (185)
2024 (167)
2025 (166)
2020 (123)
2019 (94)
2018 (62)
2017 (47)
2026 (30)
2016 (21)
2015 (10)
2008 (4)
2014 (4)
2013 (2)
2012 (1)
2011 (1)

Lab affiliation

Department of oncology UNIL CHUV Ludwig Institute for Cancer Research Lausanne Office B25A/04/94 Rue du Bugnon 25a, CH-1005 Lausanne (3)
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel (2)
Department of Chemical & Systems Biology Stanford University USA (2)
Catholic University of Leuven, Laboratory of Clinical and Experimental Endocrinology, Leuven, Belgium (1)
Jenner Institute Antigen Discovery Group University of Oxford (1)
Center of experimental therapeutics Department of oncology UNIL CHUV Ludwig Institute for Cancer Research Lausanne Centre de recherche Agora Rue du Bugnon 25A CH-1005 Lausanne (1)
Laboratory of Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, Catholic University of Leuven (1)
Attending Physician Medical Director, Brain Tumor Institute Principal Investigator, Center for Cancer and Immunology Research, Children Research Institute Associate Professor of Pediatrics - The George Washington University School of Medicine and Health Sciences Executive co-Chair, Childrens Brain Tumor Network www.CBTN.org (1)
Francis Impens, VIB-UGent Center for Medical Biotechnology, Ghent, Belgium.Department of Biomolecular Medicine, Ghent, Belgium. VIB Proteomics Core, Ghent, Belgium (1)
Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892 (1)
Department of Biochemistry, Monash University, Clayton,3168, Australia (1)
Institut Curie, Université Paris Sciences et Lettres, INSERM U932, 75005 Paris, France. (1)
Dept. Oncology-Pathology, Scilifelab, Karolinska Institutet, Stockholm, Sweden (1)
Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA 7Present address: Bristol Myers Squibb, Lawrenceville, NJ 08901, USA and Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA. (1)
Division of Immunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany (1)
Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia (1)
Head Proteomics Group, Center for Proteomics and Metabolomics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands (1)
Department of Chemical & Systems Biology, Stanford University, USA (1)
1 German Cancer Consortium of Translational Cancer Research (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany 2 IIIrd Medical Department, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany 3 Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany (1)
School of Basic Medical Sciences, Southern Medical University (1)
Head Proteomics Group , Leiden University Medical Center, Center for Proteomics and Metabolomics, PO Box 9600, Postal zone P1-Q, 2300 RC Leiden, The Netherlands (1)
Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA; The Edison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO, USA; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA (1)
University of Tübingen Interfaculty Institute for Cell Biology Department of Immunology Auf der Morgenstelle 15 72076 Tuebingen Germany (1)
Centre for Proteomic Research B85, Life Sciences Building University of Southampton University Road Highfield Southampton, Hants. SO17 1BJ United Kingdom (1)
Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany (lab head) (1)
Division of Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany Heidelberg University, Medical Faculty, Heidelberg, Germany (1)
Molecular Cell Biolody, Weizmann Institute of Science. (1)
Department of Genetics, Washington University School of Medicine, St Louis, MO, USA The Edison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO, USA McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA (1)
VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium. Department of Biomolecular Medicine, Ghent University, Ghent, Belgium. VIB Proteomics Core, VIB, Ghent, Belgium. (1)
Artificial Intelligence, Innovation Frontier Institute of Research for Science and Technology, and the Department of Electrical Engineering, College of Electrical Engineering and Computer Science, National Taiwan University of Technology, Taiwan (1)

Location

United States (10)
China (5)
Sweden (2)
Netherlands (2)
United Kingdom (2)
Thailand (1)
Singapore (1)
Germany (1)
Spain (1)
Belgium (1)
Canada (1)
Australia (1)

Keyword

Immunotherapy (10)
Neoantigen (5)
Neoantigen cancer vaccine (4)
Ipilimumab (4)
Nivolumab (4)
Adoptive cell therapy (3)
Personalized neoantigen cancer vaccine (3)
PD-1 (3)
Atezolizumab (3)
T cell receptor (2)
T lymphocyte (2)
TCR-engineered T cells (2)
Cell therapy (2)
Gene therapy (2)
Aldesleukin (2)
CTLA-4 (2)
MSS-CRC (2)
IL-2 (2)
CRC (2)
FMPV-1 (1)
Cancer-specific vaccine (1)
GM-CSF adjuvant (1)
Tumor neo-antigen DC vaccine (1)
Clinical efficacy (1)
Individualized immunotherapy (1)
Colorectal cancer vaccine (1)
Personal cancer vaccine (1)
Personalized cancer vaccine (1)
Individualized cancer vaccine (1)
Personalized (1)

Previous page
1 / 190
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 190
Next page

Sort by:

Relevance

Page size

Neoantigen targeted dendritic cell vaccine generates durable T cell responses exhibiting the full spectrum of differentiation states in NSCLC patients

Background. Dendritic cell (DC)-based neoantigen vaccination holds potential as a safe and effective adjuvant therapy for patients with early-stage, resectable NSCLC, a tumor type typically characterized by high mutational loads. DCs have the unique ability to elicit robust antitumoral T-cell respon...

ORGANISM(S): Homo sapiens (Human)

2024-03-17 | PXD044799 | Pride

Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy.

Not available

S-EPMC9559398 | biostudies-literature

A complete peptidome workflow for neoantigen identification and validation by mass spectrometry-based immunopeptidomics

We proposed a complete workflow for neoantigen identification and validation based solely on MS immunopeptidomics.We first developed a new Neo DiscoveryTM immunopeptidome enrichment Kit, which can be used for HLA peptide purification from a small amount of biopsied tissue as low as 18mg. To achieve ...

ORGANISM(S): Homo sapiens (Human)

2024-05-04 | PXD046370 | Pride

Neoantigen Immunopeptidomics Lc-ms/ms

A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.

Not available

S-EPMC8414362 | biostudies-literature

Sensitive neoantigen discovery by real-time mutanome-guided immunopeptidomics

Targeting cancer-specific HLA-peptide complexes is a promising immunotherapy approach, with mutated neoantigens offering high value for their immunogenicity and cancer-specificity. Selecting immunogenic targets requires personalized prioritization of cancer-specific immunopeptides. Mass spectrometry...

ORGANISM(S): Homo sapiens (Human)

2025-06-20 | PXD059824 | Pride

Immunopeptidomics Real-time searches Antigen discovery

NeoFox: annotating neoantigen candidates with neoantigen features.

Not available

S-EPMC9502226 | biostudies-literature

Personalized neoantigen peptide vaccine for advanced solid cancer

Interventions: Personalized neoantigen peptide vaccine consists of 15-30 long peptides combined into four distinct immunizing peptide pools with 0.3 mg of each peptide admixed with 0.5 mg poly-ICLC per pool in a volume of 1 ml.;Experimental Biological/Vaccine;Personalized Neoantigen Peptide vaccine ...

2568253 | ecrin-mdr-crc

Personalized NeoAntigen Cancer Vaccine with RT for Newly Diagnosed Glioblastoma

PRJNA429518 | ENA

Personalized NeoAntigen Cancer Vaccine with RT for Newly Diagnosed Glioblastoma

PRJNA429519 | ENA

Phenotypic Signatures of Circulating Neoantigen-Reactive CD8+ T Cells in Patients with Metastatic Cancers

PRJNA882184 | ENA

Previous page
1 / 190
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 190
Next page

Sort by:

Relevance

Page size

1895 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

IsPrivate

Submitter Keywords

First Public Date

Modelling Approach

Study status

Study type

Release Date

Lab affiliation

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets